IPP Bureau
FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
By IPP Bureau - January 21, 2026
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India
By IPP Bureau - January 21, 2026
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing
By IPP Bureau - January 21, 2026
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs
By IPP Bureau - January 21, 2026
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
By IPP Bureau - January 21, 2026
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Kindeva appoints David Stevens as new CEO
By IPP Bureau - January 20, 2026
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Alto Neuroscience bags new US patent for depression drug ALTO-207
By IPP Bureau - January 20, 2026
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Avalon clinches majority investment to expand future of diagnostic intelligence
By IPP Bureau - January 20, 2026
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Symeres rehires Jurgen Berendsen as CFO amid strategic growth push
By IPP Bureau - January 20, 2026
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis
By IPP Bureau - January 20, 2026
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
China nod to two Sanofi drugs for rare and complex conditions
By IPP Bureau - January 20, 2026
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
By IPP Bureau - January 20, 2026
Improvements were also seen in complete response rates, duration of response, and time to next treatment
China nod to first homegrown BNCT cancer drug for human trials
By IPP Bureau - January 20, 2026
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder
By IPP Bureau - January 20, 2026
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
By IPP Bureau - January 20, 2026
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
